101 related articles for article (PubMed ID: 8737639)
1. Confirmation of efficacy of etofibrate against peripheral atherosclerosis in non-human primates which model human lesion types I-VII.
Fincham JE; Quack G; Wülfroth P; Benadé AJ
Arzneimittelforschung; 1996 May; 46(5):519-25. PubMed ID: 8737639
[TBL] [Abstract][Full Text] [Related]
2. The effect of Etofibrate (Lipo-Merz) on "in vitro" cellular immune response and on lipid parameters of men with myocardial infarction and with arteriosclerosis obliterans.
Horváth M; Varsányl M; Jovanovich N; Romics L; Gerö S
Allergol Immunopathol (Madr); 1990; 18(2):95-9. PubMed ID: 2371944
[TBL] [Abstract][Full Text] [Related]
3. [Atherosclerosis treatment with etofibrate retard. New perspectives].
Degenring FH; Schatton W; Hotz W
Fortschr Med; 1983 Aug; 101(30):1391-6. PubMed ID: 6618402
[TBL] [Abstract][Full Text] [Related]
4. [Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans].
Dembińska-Kieć A; Kostka-Trabka E; Grodzińska L; Bieroń K; Kedzior A; Basista M; Zmuda A; Trabka E; Slawiński M; Czarnecka H
Fortschr Med; 1989 Jul; 107(20):450-2. PubMed ID: 2767596
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia.
Wolf HR
Drugs Exp Clin Res; 1994; 20(3):109-13. PubMed ID: 7956717
[TBL] [Abstract][Full Text] [Related]
6. Effect of etofibrate on the development and the regression of atheromas in a rabbit model of atherosclerosis.
Betz E; Quack G
Vasa; 1990; 19(2):157-60. PubMed ID: 2371790
[TBL] [Abstract][Full Text] [Related]
7. Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.
Jastrzebska M; Torbus-Lisiecka B; Pieczul-Mróz J; Chelstowski K; Kopciewicz J; Naruszewicz M
Int J Clin Pharmacol Res; 1999; 19(1):19-25. PubMed ID: 10450539
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy].
Emmerich KH; Poritis N; Stelmane I; Klindzane M; Erbler H; Goldsteine J; Görtelmeyer R
Klin Monbl Augenheilkd; 2009 Jul; 226(7):561-7. PubMed ID: 19644802
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of efficacy and safety of etofibrate in primary hyperlipidemia. A multicenter study].
dos Santos JE; Loures-Vale AA; Novazzi JP; Rabelo LM; Martinez TL
Arq Bras Cardiol; 1996 Dec; 67(6):419-22. PubMed ID: 9246832
[TBL] [Abstract][Full Text] [Related]
10. Etofibrate treatment alters low density lipoprotein susceptibility to lipid peroxidation.
Wülfroth P; Richter CM; Burkard M; Huth K; Quack G
Drugs Exp Clin Res; 1992; 18(11-12):469-74. PubMed ID: 1308472
[TBL] [Abstract][Full Text] [Related]
11. [The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy].
Dobiásová M; Frohlich J
Vnitr Lek; 2000 Mar; 46(3):152-6. PubMed ID: 11048517
[TBL] [Abstract][Full Text] [Related]
12. Effect of etofibrate and its metabolites on atheromas of rabbits and on smooth muscle cell cultures.
Betz E; Hämmerle H
Arzneimittelforschung; 1986; 36(1):92-8. PubMed ID: 3954822
[TBL] [Abstract][Full Text] [Related]
13. [Lipid changes of fibrinogen and of platelet aggregation induced by etofibrate].
Fonseca FA; Novazzi JP; Cendoroglo MS; Duarte M; Almeida Pinto LE; Rabelo LM; da Rocha Martinez TL
Arq Bras Cardiol; 1996 Jan; 66(1):33-5. PubMed ID: 8731322
[TBL] [Abstract][Full Text] [Related]
14. Bioavailability studies of etofibrate in rhesus monkeys.
Waller AR; Chasseaud LF; Taylor T; Schatton W
Arzneimittelforschung; 1985; 35(2):489-92. PubMed ID: 4039571
[TBL] [Abstract][Full Text] [Related]
15. Atheroprotective effect of exogenous heparin-derivative treatment on the aortic disturbances and lipoprotein oxidation in hypercholesterolemic diet fed rats.
Deepa PR; Varalakshmi P
Clin Chim Acta; 2005 May; 355(1-2):119-30. PubMed ID: 15820486
[TBL] [Abstract][Full Text] [Related]
16. A diet-induced hypercholesterolemic murine model to study atherogenesis without obesity and metabolic syndrome.
Hartvigsen K; Binder CJ; Hansen LF; Rafia A; Juliano J; Hörkkö S; Steinberg D; Palinski W; Witztum JL; Li AC
Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):878-85. PubMed ID: 17255537
[TBL] [Abstract][Full Text] [Related]
17. Effect of valium (diazepam) on experimental atherosclerosis in roosters.
Patel DJ; Wong HY; Newman HA; Nightingale TE; Frasinel C; Johnson FB; Patel S; Coleman B
Artery; 1982; 10(4):237-49. PubMed ID: 7181670
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice.
Nachtigal P; Pospisilova N; Jamborova G; Pospechova K; Solichova D; Andrys C; Zdansky P; Micuda S; Semecky V
Life Sci; 2008 Mar; 82(13-14):708-17. PubMed ID: 18289605
[TBL] [Abstract][Full Text] [Related]
19. Epigallocatechin gallate improves serum lipid profile and erythrocyte and cardiac tissue antioxidant parameters in Wistar rats fed an atherogenic diet.
Ramesh E; Elanchezhian R; Sakthivel M; Jayakumar T; Senthil Kumar RS; Geraldine P; Thomas PA
Fundam Clin Pharmacol; 2008 Jun; 22(3):275-84. PubMed ID: 18485145
[TBL] [Abstract][Full Text] [Related]
20. [Lipanor treatment of atherogenic hyperlipoproteinemia].
Susekov AV; Tvorogova MG; Arabidze GG; Kukharchuk VV
Ter Arkh; 1998; 70(9):57-61. PubMed ID: 9821228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
